OTCMKTS:ATMS

Artemis Therapeutics Stock Forecast, Price & News

$0.42
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.42
Now: $0.42▼
$0.42
50-Day Range
$0.25
MA: $0.31▼
$0.53
52-Week Range
$0.03
Now: $0.42▼
$2.00
VolumeN/A
Average Volume6,009 shs
Market Capitalization$2.16 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.38
Artemis Therapeutics Inc. does not have significant operations. Previously, it was engaged in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company was incorporated in 1997 and is based in New York, New York.
Artemis Therapeutics logo

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Miscellaneous chemical products
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ATMS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.artemis-therapeutics.com
Phone646-233-1454
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio0.04
Quick Ratio0.04

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.05) per share
Price / Book-8.40

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-120,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-227.03%

Miscellaneous

Outstanding Shares5,154,000
Market Cap$2.16 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Artemis Therapeutics (OTCMKTS:ATMS) Stock Price Up 16.7%
April 13, 2021 |  americanbankingnews.com
Lineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% Upside
November 18, 2020 |  seekingalpha.com
Artemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral Infections
January 21, 2019 |  finance.yahoo.com
New Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
January 21, 2019 |  finance.yahoo.com
Data Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
January 21, 2019 |  finance.yahoo.com
Artemis Therapeutics Announces Two Recent Publications Highlighting Artemisone's Activity Against Human Cytomegalovirus And Malaria
January 21, 2019 |  finance.yahoo.com
See More Headlines

MarketRank™

Overall MarketRank™

0.46 out of 5 stars

Medical Sector

1654th out of 2,021 stocks

Miscellaneous Chemical Products Industry

14th out of 15 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.42
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATMS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Artemis Therapeutics (OTCMKTS:ATMS) Frequently Asked Questions

What stocks does MarketBeat like better than Artemis Therapeutics?

Wall Street analysts have given Artemis Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Artemis Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Artemis Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Artemis Therapeutics' stock was trading at $0.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATMS stock has increased by 320.0% and is now trading at $0.42.
View which stocks have been most impacted by COVID-19.

Who are Artemis Therapeutics' key executives?

Artemis Therapeutics' management team includes the following people:
  • Mr. Chanan Morris, Chief Financial Officer (Age 55, Pay $42k)
  • Dr. Dana Wolf, Chief Scientific Officer (Age 64)
  • Mr. Israel Alfassi, Director & CEO of Artemis Pharma, Inc. (Age 52)

Who are some of Artemis Therapeutics' key competitors?

Some companies that are related to Artemis Therapeutics include Element Solutions (ESI), WD-40 (WDFC), Cabot (CBT), Orion Engineered Carbons (OEC), Flotek Industries (FTK), Advanced Emissions Solutions (ADES), PURE Bioscience (PURE), Flexible Solutions International (FSI), VerifyMe (VRME), HighCom Global Security (HCGS), Ener-Core (ENCR), GlyEco (GLYE) and Summit Environmental (SEVT).
View all of ATMS's competitors.

What is Artemis Therapeutics' stock symbol?

Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS."

How do I buy shares of Artemis Therapeutics?

Shares of ATMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Artemis Therapeutics' stock price today?

One share of ATMS stock can currently be purchased for approximately $0.42.

How much money does Artemis Therapeutics make?

Artemis Therapeutics has a market capitalization of $2.16 million.

What is Artemis Therapeutics' official website?

The official website for Artemis Therapeutics is www.artemis-therapeutics.com.

Where are Artemis Therapeutics' headquarters?

Artemis Therapeutics is headquartered at 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003.

How can I contact Artemis Therapeutics?

Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The company can be reached via phone at 646-233-1454 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.